This may be therapeutically desirable when CSPGs like aggrecan increase to ameliorate the earlier inflammatory stages of MS, but therapeutically problematic when other CSPGs such as versican increase, that inhibit remyelination and repair in later phases of the disease. This evidence concerns the gene ACAN and myeloid sarcoma.